The Chemours Company (NYSE:CC - Free Report) - Investment analysts at Zacks Research dropped their Q2 2025 earnings estimates for Chemours in a report released on Wednesday, July 9th. Zacks Research analyst R. Department now forecasts that the specialty chemicals company will post earnings of $0.40 per share for the quarter, down from their prior forecast of $0.47. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q3 2025 earnings at $0.48 EPS, FY2025 earnings at $1.32 EPS, Q1 2026 earnings at $0.35 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.70 EPS, Q4 2026 earnings at $0.41 EPS, FY2026 earnings at $2.10 EPS, Q1 2027 earnings at $0.49 EPS and FY2027 earnings at $2.44 EPS.
Other equities research analysts also recently issued reports about the stock. UBS Group lowered their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Mizuho set a $15.00 target price on shares of Chemours in a report on Tuesday, April 15th. Royal Bank Of Canada boosted their target price on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Thursday, July 3rd. Morgan Stanley lowered their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Finally, The Goldman Sachs Group lowered their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $17.33.
Get Our Latest Research Report on Chemours
Chemours Trading Down 1.7%
Shares of NYSE CC traded down $0.24 during midday trading on Thursday, reaching $13.81. 3,892,089 shares of the stock were exchanged, compared to its average volume of 2,543,553. Chemours has a 52-week low of $9.13 and a 52-week high of $25.54. The stock has a 50 day moving average price of $11.38 and a 200-day moving average price of $13.91. The company has a market capitalization of $2.07 billion, a P/E ratio of 69.05 and a beta of 1.65. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01.
Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. The business's quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share.
Chemours Dividend Announcement
The firm also recently declared a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were given a dividend of $0.0875 per share. The ex-dividend date was Friday, May 16th. This represents a yield of 3.17%. Chemours's dividend payout ratio (DPR) is 175.00%.
Insider Buying and Selling
In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The shares were purchased at an average cost of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer directly owned 59,694 shares in the company, valued at approximately $673,348.32. This represents a 8.06% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Damian Gumpel purchased 13,400 shares of Chemours stock in a transaction on Monday, June 2nd. The shares were acquired at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the completion of the transaction, the insider owned 123,879 shares of the company's stock, valued at $1,142,164.38. This represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 25,672 shares of company stock worth $251,573. 0.34% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC lifted its position in shares of Chemours by 4.7% during the fourth quarter. Corient Private Wealth LLC now owns 13,428 shares of the specialty chemicals company's stock worth $227,000 after purchasing an additional 604 shares in the last quarter. HUB Investment Partners LLC lifted its position in shares of Chemours by 1.4% during the fourth quarter. HUB Investment Partners LLC now owns 58,250 shares of the specialty chemicals company's stock worth $984,000 after purchasing an additional 821 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in Chemours by 39.3% in the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after acquiring an additional 1,003 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in Chemours by 100.4% in the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after acquiring an additional 1,119 shares in the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.
Chemours Company Profile
(
Get Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Articles
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
